Verastem (VSTM)
(Delayed Data from NSDQ)
$2.96 USD
-0.01 (-0.34%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.97 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Verastem (VSTM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.21 | $36.00 | $7.00 | 580.47% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Verastem comes to $20.21. The forecasts range from a low of $7.00 to a high of $36.00. The average price target represents an increase of 580.47% from the last closing price of $2.97.
Analyst Price Targets (7 )
Broker Rating
Verastem currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/VSTM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.13 | 1.13 | 1.13 | 1.13 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
5/29/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
5/29/2024 | Alliance Global Partners | James Molloy | Not Available | Strong Buy |
5/12/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
5/10/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Strong Buy | Strong Buy |
3/19/2024 | H.C. Wainwright & Co. | Sean Lee | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.13 |
ABR (Last week) | 1.13 |
# of Recs in ABR | 8 |
Average Target Price | $20.21 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -1.06 |